- Home
- HYFM vs OSRH Comparison
HYFM vs OSRH Comparison
Compare HYFM & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HYFM | OSRH |
|---|---|---|
| Founded | 1977 | N/A |
| Country | United States | United States |
| Employees | N/A | 21 |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2M | 11.7M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | HYFM | OSRH |
|---|---|---|
| Price | $0.85 | $0.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 35.5K | ★ 785.7K |
| Earning Date | 05-12-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $134,252,000.00 | N/A |
| Revenue This Year | $57.44 | $9.30 |
| Revenue Next Year | $5.71 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.79 | $0.38 |
| 52 Week High | $4.78 | $1.79 |
Technical Indicators
Market Signals| Indicator | HYFM | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | 41.67 | 59.49 |
| Support Level | $0.86 | $0.55 |
| Resistance Level | $1.33 | $0.60 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 27.44 | 71.49 |
Price Performance
Historical ComparisonAbout HYFM Hydrofarm Holdings Group Inc.
Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.
About OSRH OSR Holdings Inc.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.